Aytu BioPharma, Inc. reported earnings results for the full year ended June 30, 2023. For the full year, the company reported net loss was USD 17.05 million compared to USD 108.78 million a year ago. Basic loss per share from continuing operations was USD 5.11 compared to USD 74.01 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.904 USD | +2.26% | +4.10% | +2.26% |
Feb. 14 | Transcript : Aytu BioPharma, Inc., Q2 2024 Earnings Call, Feb 14, 2024 | |
Feb. 14 | Earnings Flash (AYTU) AYTU BIOPHARMA Reports Q2 Revenue $22.9M, vs. Street Est of $21.75M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.26% | 16.17M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- AYTU Stock
- News Aytu BioPharma, Inc.
- Aytu BioPharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023